pSivida: Out-licensing of BioSiliconTM to PureTech Development LLC
Global nanotechnology company pSivida Limited announced that it has signed an agreement with US based PureTech Development LLC ("Puretech") to investigate and evaluate out-licensing opportunities for BioSiliconTM with an emphasis on tissue engineering, wound management and orthopedics.
Through a range of collaborative partnerships and internal R&D over the last four years, pSivida has developed the BioSiliconTM (nano-structured porous elemental silicon) technology platform in non-core areas such as tissue engineering, wound management and orthopedics to a point where it is in a position and in line with the Company's broader commercialization strategy, to seek suitable partners in these specialist areas of healthcare.
pSivida has commissioned PureTech to explore with suitable partners, arrangements for evaluating the potential of BioSiliconTM in their areas of expertise and such partnerships would be expected to produce, in due course, revenue in the form of upfront and milestone payments as BioSiliconTM based products are developed and commercialized.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Maple_syrup_urine_disease
Field_dressing_(bandage)
Discovery highlights promise of new immune system-based therapies
Category:Molecular_biology_institutes

BASF invests in start-up 3Helix Inc. - Companies want to jointly bring collagen-hybridizing peptide solutions to the personal care market

Unexpected Helpers in Wound Healing

Bayer aims to sustainably improve performance with new organization - New operating model aims to reduce hierarchies, eliminate bureaucracy and accelerate decision-making processes
Genome sequence of hypertensive rat expected to uncover the genetic basis of hypertension in humans
Haplogroup_J_(Y-DNA)
National_Physicians_Alliance
Some large molecules sneak across skin on their own
